Oxytocin, Stress, Craving, Opioid Use Disorder
Key facts
- Who runs it
- Brown University
- Where
- Providence, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 20 people enrolled
- Started
- 6 Jan 2020
- Ended
- 23 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- intranasal oxytocin, 40 IU, twice a day for 7 days
- Record updated
- 25 May 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or female (50%), 18 to 70 (inclusive) years of age
- Currently meets DSM-5 criteria for OUD
- Currently on a stable dose of buprenorphine/naloxone or methadone for at least 3 months
- In good health as confirmed by medical history, physical examination and blood work (Liver function within 5x the Upper normal limits (AST/ALT) and renal function within 2x the Lower Normal Limit (bilirubin, creatine clearance)
- Willing to take medication and adhere to the study procedures;- Understand informed consent and questionnaires in English at an 8th grade level
- Clinical Opiate Withdrawal Scale (COWS) = 0 at study screening and prior laboratory sessions
Who cannot take part
- Current use of medications that may interact with study medications
- Clinically significant electrolyte abnormalities, current rhinitis or use of vasoconstricting medications or prostaglandins
- Current substance disorder other than marijuana, nicotine and caffeine as assessed by self-report and urine toxicology screen at baseline
- History of hypersensitivity to study medications
- Women who are breastfeeding, test positive for pregnancy or are unwilling to use medically-approved birth control
- Suicide attempts in the last three months
Where in United States
- Brown UniversityProvidence, United States
About the trial
What the trial wants to find out
Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. The long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (OUD) in order to better understand how they can be effectively treated.
The 2 groups in the trial
- Oxytocin first, then placeboTreatment being tested
Oxytocin was administered as 40 IU/0.12 mL nasal spray in each nostril once in the morning and once in the afternoon for 7 days. After a 2 day washout period, Placebo was administered as nasal spray in each nostril once in the morning and once in the afternoon for 7 days.
Treatment: intranasal oxytocin, 40 IU, twice a day for 7 days
- Matching placebo, then oxytocinPlacebo, for comparison
Placebo was administered as nasal spray in each nostril once in the morning and once in the afternoon for 7 days. After a 2 day washout period, oxytocin was administered as 40 IU/0.12 mL nasal spray in each nostril once in the morning and once in the afternoon for 7 days.
Treatment: intranasal oxytocin, 40 IU, twice a day for 7 days
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Oxytocin to Reduce Stress-induced Craving in Individuals With Opioid Use Disorder
- Record updated
- 25 May 2025